Zala Carlos, Rustad Clare A, Chan Keith, Khan Nabeela I, Beltran Marcelo, Warley Eduardo, Ceriotto Mariana, Druyts Eric F, Hogg Robert S, Montaner Julio, Cahn Pedro
Fundacion Dra. Cecilia Grierson, Buenos Aires, Argentina.
Medscape J Med. 2008 Apr 2;10(4):78.
To report emerging data on the use of highly active antiretroviral therapy (HAART) in Argentina by assessing patterns of HAART access and late vs early treatment initiation in a population-based cohort of adults infected with HIV type-1.
The Prospective Study on the Use and Monitoring of Antiretroviral Therapy (PUMA) is a study of 883 HIV-positive individuals enrolled in the Argentinean drug treatment program. Individuals were 16 years of age and older and were recruited from 10 clinics across Argentina.
Sociodemographic and clinical characteristics were examined using contingency tables (Pearson chi-square test and Fisher exact test) for categoric variables and Wilcoxon rank-sum test for continuous variables. To analyze time to initiation of HAART we used Kaplan-Meier methods and Cox regression.
Patients who initiated HAART were more likely to be older, have an AIDS-defining illness, be an injection drug user (IDU), have a lower median CD4 cell count, have a higher median viral load, and be less likely to be men who have sex with men (MSM). In multivariate analysis, AIDS-defining illness and plasma viral load were significantly associated with time to starting therapy. Patients who received late access were more likely to be diagnosed with AIDS and have higher median plasma viral loads than those receiving early access.
Our results indicate that despite free availability of treatment, monitoring, and care in Argentina, a significant proportion of men and women are accessing HAART late in the course of HIV disease. Further characterization of the HIV-positive population will allow for a more comprehensive evaluation of the impact of HAART within the Argentinean drug treatment program.
通过评估基于人群的1型艾滋病毒感染成年队列中高效抗逆转录病毒疗法(HAART)的使用模式以及延迟与早期开始治疗的情况,报告阿根廷使用HAART的新出现的数据。
抗逆转录病毒疗法使用与监测前瞻性研究(PUMA)是一项对883名参加阿根廷药物治疗项目的艾滋病毒阳性个体进行的研究。个体年龄在16岁及以上,从阿根廷各地的10家诊所招募。
使用列联表(Pearson卡方检验和Fisher精确检验)分析分类变量的社会人口统计学和临床特征,使用Wilcoxon秩和检验分析连续变量。为了分析开始HAART的时间,我们使用了Kaplan-Meier方法和Cox回归。
开始使用HAART的患者更可能年龄较大、患有艾滋病定义疾病、是注射吸毒者(IDU)、CD4细胞计数中位数较低、病毒载量中位数较高,并且较不可能是男男性行为者(MSM)。在多变量分析中,艾滋病定义疾病和血浆病毒载量与开始治疗的时间显著相关。与早期获得治疗的患者相比,延迟获得治疗的患者更可能被诊断为艾滋病且血浆病毒载量中位数更高。
我们的结果表明,尽管在阿根廷治疗、监测和护理可免费获得,但仍有很大比例的男性和女性在艾滋病毒疾病病程后期才开始使用HAART。对艾滋病毒阳性人群的进一步特征描述将有助于更全面地评估HAART在阿根廷药物治疗项目中的影响。